B. J. Veldt, Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus, Hepatology, vol.47, pp.1856-62, 2008.

R. H. Westbrook and G. Dusheiko, Natural history of hepatitis C, J Hepatol, vol.61, issue.14, pp.481-485, 2014.

J. P. Messina, Global distribution and prevalence of hepatitis C virus genotypes, Hepatology, vol.61, pp.77-87, 2015.

Y. A. Mohamoud, G. R. Mumtaz, S. Riome, D. Miller, and L. J. Abu-raddad, The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis, BMC Infect Dis, vol.13, 2013.

A. A. Mohamed, Hepatitis C virus: A global view, World J Hepatol, vol.7, pp.2676-80, 2015.

J. W. Ward, The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease, Top Antivir Med, vol.21, pp.15-24, 2013.

J. C. Meunier, Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus, J Virol, vol.82, pp.966-973, 2008.

B. Bartosch, Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor, J Biol Chem, vol.278, 2003.

K. Mccaffrey, H. Gouklani, I. Boo, P. Poumbourios, and H. E. Drummer, The variable regions of hepatitis C virus glycoprotein E2 have an essential structural role in glycoprotein assembly and virion infectivity, J Gen Virol, vol.92, pp.112-121, 2011.

P. Zhang, Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma, Proc Natl Acad Sci U S A, vol.104, pp.8449-8454, 2007.

Y. S. El-abd, Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2, Virol J, vol.8, p.391, 2011.

M. Law, Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge, Nat Med, vol.14, pp.25-27, 2008.

J. Schulze-zur-wiesch, Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes, J Immunol, vol.175, pp.3603-3613, 2005.

A. Grakoui, HCV persistence and immune evasion in the absence of memory T cell help, Science, vol.302, pp.659-662, 2003.

N. H. Shoukry, Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection, J Exp Med, vol.197, pp.1645-1655, 2003.

P. S. Sung, V. Racanelli, and E. C. Shin, CD8(+) T-cell responses in acute Hepatitis C virus infection, Front Immunol, vol.5, p.266, 2014.

A. J. Freeman, The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection, J Hepatol, vol.38, pp.349-356, 2003.

J. Torresi, D. Johnson, and H. Wedemeyer, Progress in the development of preventive and therapeutic vaccines for hepatitis C virus, J Hepatol, vol.54, issue.11, pp.18-21, 2011.

C. I. Yu and B. L. Chiang, A new insight into hepatitis C vaccine development, J Biomed Biotechnol, p.548280, 2010.

D. T. O'hagan, Cationic microparticles are a potent delivery system for a HCV DNA vaccine, Vaccine, vol.23, pp.672-680, 2004.

A. A. Haller, Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins, Vaccine, vol.25, issue.06, pp.1171-1177, 2007.

D. Drane, Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers, Hum Vaccin, vol.5, pp.151-157, 2009.

C. Firbas, Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects, Vaccine, vol.24, issue.06, pp.273-281, 2006.

S. Yutani, Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles, Cancer Sci, vol.100, 1935.

T. H. Abdelhafez, Mice antibody response to conserved Nonadjuvanted multiple antigenic peptides derived from E1/E2 regions of Hepatitis C virus

L. Alvarez-lajonchere, Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial, J Viral Hepat, vol.16, pp.156-167, 2009.

L. Kuhs and K. A. , Peripheral immunization induces functional intrahepatic hepatitis C specific immunity following selective retention of vaccine-specific CD8 T cells by the liver, Hum Vaccin, vol.7, pp.1326-1335, 2011.

K. A. Lang, J. Yan, R. Draghia-akli, A. Khan, and D. B. Weiner, Strong HCV NS3-and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine, Vaccine, vol.26, pp.954-961, 2008.

L. Alvarez-lajonchere and S. Duenas-carrera, Advances in DNA immunization against hepatitis C virus infection, Hum Vaccin, vol.5, pp.568-571, 2009.

F. Habersetzer, A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C, Gastroenterology, vol.141, issue.11, pp.766-775, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00827965

I. Echeverria, Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells, Hepatology, vol.54, pp.28-37, 2011.

A. C. Jirmo, Monocytes transduced with lentiviral vectors expressing hepatitis C virus non-structural proteins and differentiated into dendritic cells stimulate multi-antigenic CD8(+) T cell responses, Vaccine, vol.28, pp.922-933, 2010.

M. Puig, CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus, Hepatology, vol.44, pp.736-781, 2006.

J. Bukh, R. H. Miller, and R. H. Purcell, Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes, Semin Liver Dis, vol.15, pp.41-63, 1995.

P. Simmonds, Sequence variability in the 5? non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity, J Gen Virol, vol.74, pp.661-669, 1993.

M. Y. Omran, . Ss;-el, . Garf, and A. A. Wt;-tabll,

. Bader-el-din, K. Ng;-atef, W. Nabil, and M. K. Awady, Phylogenetic and Genotyping of Hepatitis C Virus in Egypt

, Australian J of Basic and Applied Sciences, vol.3, pp.1-8, 2009.

W. Abdel-razek and I. Waked, Optimal therapy in genotype 4 chronic hepatitis C: finally cured?, Liver Int, vol.35, issue.1, pp.27-34, 2015.

K. Yusim, Los alamos hepatitis C immunology database, Appl Bioinformatics, vol.4, pp.217-225, 2005.

P. Sabet and L. , Immunogenicity of multi-epitope DNA and peptide vaccine candidates based on Core, E2, NS3 and NS5B HCV epitopes in BALB/c mice, Hepat Mon, vol.14, p.22215, 2014.

X. J. Huang, Cellular immunogenicity of a multi-epitope peptide vaccine candidate based on hepatitis C virus NS5A, NS4B and core proteins in HHD-2 mice, J Virol Methods, vol.189, issue.13, pp.8-14, 2013.

A. Ghaffar, E. A. , E. Shabrawy, and O. , Review of the medical research ethics committee (MREC), Curr Med Res Opin, vol.29, pp.1411-1418, 2003.

T. Wakita, Production of infectious hepatitis C virus in tissue culture from a cloned viral genome, Nat Med, vol.11, pp.791-796, 2005.

D. Delgrange, Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins, J Gen Virol, vol.88, pp.2495-2503, 2007.

L. Goueslain, Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication, J Virol, vol.84, pp.773-787, 2010.

T. K. Scheel, Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization, Proc Natl Acad Sci U S A, vol.105, pp.997-1002, 2008.

Z. Y. Keck, Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate, PLoS Pathog, vol.8, p.1002653, 2012.

H. Nakabayashi, K. Taketa, K. Miyano, T. Yamane, and J. Sato, Growth of human hepatoma cells lines with differentiated functions in chemically defined medium, Cancer Res, vol.42, pp.3858-63, 1982.

J. Dubuisson, Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses, J Virol, vol.68, pp.6147-60, 1994.

H. M. Diepolder, Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection, Lancet, vol.346, issue.95, pp.91691-91692, 1995.

J. T. Gerlach, Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C, Gastroenterology, vol.117, pp.933-941, 1999.

A. Ulsenheimer, Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C, Hepatology, vol.37, pp.1189-1198, 2003.

J. Schmidt, H. E. Blum, and R. Thimme, T-cell responses in hepatitis B and C virus infection: similarities and differences, Emerg Microbes Infect, vol.2, 2013.

A. Wahid and J. Dubuisson, Virus-neutralizing antibodies to hepatitis C virus, J Viral Hepat, vol.20, pp.369-76, 2013.

M. Esumi, Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees, Arch Virol, vol.144, pp.973-80, 1999.

P. T. Vietheer, The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in Guinea pigs, Hepatology, vol.65, pp.1117-1148, 2017.

D. Shang, W. Zhai, and J. P. Allain, Broadly cross-reactive, high-affinity antibody to hypervariable region 1 of the hepatitis C virus in rabbits, Virology, vol.258, issue.99, pp.99730-99731, 1999.

R. A. Urbanowicz, A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance, J Virol, vol.90, pp.3288-301, 2015.

,

T. J. Morin, Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees, PLoS Pathog, vol.8, p.1002895, 2012.

J. C. Meunier, Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus, J Infect Dis, vol.204, pp.1186-1190, 2011.

D. Li, Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice, J Virol, vol.90, pp.10486-10498, 2016.

N. Shoukry and H. Hepatitis, C vaccines, antibodies, and T cells, Front Immunol, vol.9, p.1480, 2018.

S. E. Frey, Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults, Vaccine, vol.28, issue.10, pp.925-929, 2010.

S. B. Cashman, B. D. Marsden, and L. B. Dustin, The Humoral immune response to HCV: understanding is key to vaccine development, Front Immunol, vol.5, p.550, 2014.

T. Taguchi, Hepatitis C virus NS5A protein interacts with 2?,5?-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner, J Gen Virol, vol.85, pp.959-69, 2004.

S. J. Polyak, Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response, J Virol, vol.75, pp.6095-106, 2001.

T. Abe, Hepatitis C virus nonstructural protein 5A modulates the tolllike receptor-MyD88-dependent signaling pathway in macrophage cell lines, J Virol, vol.81, pp.649-656, 2007.

M. K. Ibrahim, Transcriptional Dysregulation of Upstream Signaling of IFN Pathway in Chronic HCV Type 4 Induced Liver Fibrosis, PLoS One, vol.11, p.154512, 2016.

C. B. Bigger, Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees, J Virol, vol.78, pp.13779-13792, 2004.

Q. He, C. S. Graham, D. Mangoni, E. Koziel, and M. J. , Differential expression of toll-like receptor mRNA in treatment non-responders and sustained virologic responders at baseline in patients with chronic hepatitis C, Liver Int, vol.26, pp.1100-1110, 2006.

N. H. Gruner, Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C, J Infect Dis, vol.181, pp.1528-1536, 2000.

S. Urbani, Virus-specific CD8+ lymphocytes share the same effectormemory phenotype but exhibit functional differences in acute hepatitis B and C, J Virol, vol.76, pp.12423-12457, 2002.

H. Wedemeyer, Impaired effector function of hepatitis C virusspecific CD8+ T cells in chronic hepatitis C virus infection, J Immunol, vol.169, pp.3447-58, 2002.

M. E. Major, Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees, Hepatology, vol.39, pp.1709-1729, 2004.

T. Kanda, R. Steele, R. Ray, and R. B. Ray, Inhibition of intrahepatic gamma interferon production by hepatitis C virus nonstructural protein 5A in transgenic mice, J Virol, vol.83, pp.8463-8469, 2009.

M. Frese, Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs, Hepatology, vol.35, pp.694-703, 2002.

, Publisher's Note

, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations